Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Innoplexus AG currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are all located within 1 distinct art unit, indicating a highly concentrated technical focus. However, the prosecution is distributed among 3 distinct examiners.
STUBBS, JOHN THOMAS is the busiest examiner for the company, with 1 pending office action. This means each of the 3 distinct examiners is handling one of the 3 pending office actions. While the technology is focused in 1 distinct art unit, the company must interact with three different individuals to advance its portfolio.
Practitioners should note that while the 1 distinct art unit provides a consistent procedural framework, the 3 distinct examiners may have different interpretations. The strategy for Innoplexus AG involves coordinating responses across these 3 pending office actions. Success in the Biotechnology & Pharmaceuticals sector will depend on navigating the specific preferences of each examiner within that single unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| §101 + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STUBBS, JOHN THOMAS | 1 | — | — |
| WOITACH, JOSEPH T | 1 | 49.9% | +28.3% |
| MPAMUGO, CHINYERE | 1 | 28.5% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18362199 | SYSTEM AND METHOD FOR AIDING DRUG DEVELOPMENT | STUBBS, JOHN THOMAS | — |
| 18308191 | SYSTEM AND METHOD FOR IDENTIFYING MOLECULAR PATHWAYS PERTURBED UNDER INFLUENCE OF DRUG OR DISEASE | WOITACH, JOSEPH T | — |
| 17981954 | METHOD AND SYSTEM FOR GENERATING A GRAPH NEURAL NETWORK COMPRISING ASSOCIATION OF ONE OR MORE ORGANS WITH A DISEASE | MPAMUGO, CHINYERE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18308191 | SYSTEM AND METHOD FOR IDENTIFYING MOLECULAR PATHWAYS PERTURBED UNDER INFLUENCE OF DRUG OR DISEASE | WOITACH, JOSEPH T | — |
| 17981954 | METHOD AND SYSTEM FOR GENERATING A GRAPH NEURAL NETWORK COMPRISING ASSOCIATION OF ONE OR MORE ORGANS WITH A DISEASE | MPAMUGO, CHINYERE | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18362199 | SYSTEM AND METHOD FOR AIDING DRUG DEVELOPMENT | STUBBS, JOHN THOMAS | — | §101§102§103§112 | Non-Final OA | — | Pending | Jul 31, 2023 |
| 18308191 | SYSTEM AND METHOD FOR IDENTIFYING MOLECULAR PATHWAYS PERTURBED UNDER INFLUENCE OF DRUG OR DISEASE | WOITACH, JOSEPH T | — | §101§103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 17981954 | METHOD AND SYSTEM FOR GENERATING A GRAPH NEURAL NETWORK COMPRISING ASSOCIATION OF ONE OR MORE ORGANS WITH A DISEASE | MPAMUGO, CHINYERE | 1686 | §101 | Non-Final OA | — | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial